Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
JS Garcia, HT Kim, HM Murdock, CS Cutler… - Blood …, 2021 - ashpublications.org
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …
chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity …
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
JP Bewersdorf, A Derkach, L Gowda… - Leukemia & …, 2021 - Taylor & Francis
The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial
venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT …
venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT …
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA+ RIC in Patients with High-Risk Myeloid Malignancies
F Schulz, P Jäger, J Tischer, A Fraccaroli, G Bug… - Cancers, 2024 - mdpi.com
Simple Summary Allogeneic stem cell transplantation (aHSCT) is the only potentially
curative treatment option for patients with high-risk myeloid malignancies. Depending on the …
curative treatment option for patients with high-risk myeloid malignancies. Depending on the …
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia
M Byrne, N Danielson, S Sengsayadeth… - American Journal of …, 2020 - Wiley Online Library
For patients with high risk myeloid disease, allogeneic hematopoietic cell transplantation
(HCT) is the only potentially curative therapy. Unfortunately, many of these patients relapse …
(HCT) is the only potentially curative therapy. Unfortunately, many of these patients relapse …
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML
Pediatric patients with relapsed/refractory acute myeloid leukemia (rAML) have a poor
prognosis. Novel treatment options are needed to safely and effectively reduce disease …
prognosis. Novel treatment options are needed to safely and effectively reduce disease …
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
A Kent, M Schwartz, C McMahon, M Amaya… - Bone Marrow …, 2023 - nature.com
Relapse is the most common cause of mortality in acute myeloid leukemia (AML) patients
after allogeneic stem cell transplant (SCT). Post-SCT maintenance strategies that prevent …
after allogeneic stem cell transplant (SCT). Post-SCT maintenance strategies that prevent …
[HTML][HTML] Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse
Relapse is the most common cause of mortality in patients undergoing allogeneic stem cell
transplantation (ASCT) for acute myeloid leukemia (AML). The presence of measurable …
transplantation (ASCT) for acute myeloid leukemia (AML). The presence of measurable …
Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
X Cao, J Chen, H Wang, W Ma, W Liu, F Zhang… - Annals of …, 2023 - Taylor & Francis
Background Venetoclax monotherapy is an effective option for patients with acute myeloid
leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning …
leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning …
Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic …
Y Wei, X Xiong, X Li, W Lu, X He, X Jin, R Sun… - Cancer …, 2021 - Wiley Online Library
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem …
A Zucenka, V Vaitekenaite, K Maneikis… - Bone Marrow …, 2021 - nature.com
We retrospectively compared the outcomes of 20 patients receiving Venetoclax+ low-dose
Cytarabine+ Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida as salvage …
Cytarabine+ Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida as salvage …